TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants with Primary Adverse Events (PAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Freedom from Documented Atrial Fibrillation, Atrial Tachycardia, or Atrial Flutter Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of time device in situ on patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of times device removed by patient / other
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of waveform data collected while in situ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleeping habits
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Intention to Quit Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Intention to Purchase Cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recovery Room Numeric Rating Scale Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Operating and Recovery Room Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change The Canadian Occupational Performance Measure (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Length of stay in Therapeutic Community
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Performance in the Therapeutic Community
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in severity of suicidal ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of participants achieving TI for ≥ 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life related to skin disease
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of Neutralizing IgG antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of adverse events occurring during arteriovenous fistula puncture
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of surgeries with Critical View of Safety achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Amount of secondary hospitalisations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change of Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Change of scores of Visual analogue scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change of Dermatology Life Quality Index (questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of solicited AEs within 7 days after each vaccination dose
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of unsolicited AEs within 28 days after each vaccination dose
Endpoint domain: Adverse events/effects
Primary endpoint: SAE, MAAE in all subjects within 12 months after the completion of the vaccination series
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade 3-5 non-hematologic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage change in Yale-Brown Obsessive-Compulsive Scale (YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HDV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep and light sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: sentence comprehension performance - accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sentence comprehension performance - reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of completed co-managed visits via videoconferencing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Headache impact test (HIT-6)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The days of migraine remission (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge on dietary supplements
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum voluntary isometric contraction of the triceps surae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum evoked torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle fatigue assessment during the muscle fatigue protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Levels of TFV in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: membrane lung oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAS-J-cog-14 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ureteral Stent related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of ED attendance related to mental health issues
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Nausea Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: proportion of cure at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment emergent adverse events (TEAE's)
Endpoint domain: Adverse events/effects
Primary endpoint: Help Seeking Intentions - Post-Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Help Seeking Intentions - Follow-Up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in prosocial behavior
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in individual prosocial behavior
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in social competence
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: serum Inhibin B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum Anti Mullerian Hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: maximally tolerated dose of DLI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Troponin I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major pathologic response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Naldemedine and Nor-naldemedine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Achieve Maximum Plasma Concentration (Tmax) of Naldemedine and Nor-naldemedine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of Naldemedine and Nor-naldemedine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-emergent adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Clotting kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rest cerebral blood flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Local Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: ctDNA amount comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilirubin serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the ethinylestradiol plasma concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the levonorgestrel plasma concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC value of 1-month drug resistance/relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in child irritability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in child-parent relationship
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Parent perception of change in child emotion regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Chain in Serum Short Chain Fatty Acids (SCFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Colonization or infection with C. difficile
Endpoint domain: Adverse events/effects
Primary endpoint: Change in peak esophageal muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of COVID-19 cases
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rates of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: low anterior resection syndrome score (LARS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage change in Total Symptom Score (TSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absolute change in Total Symptom Score (TSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of report of domain assessed by Patients' Global Impression of Change (PGIC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Adolescent Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Calibration of Prospera® test for T cell mediated rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Calibration of Prospera® test for antibody-mediated rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Calibration of Prospera® test for lung injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: N170 Latency to Upright Human Faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oculomotor Index of Gaze to Human Faces (OMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Enablers and barriers to use telemedicine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to pay for telemedicine tools
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: FcRn Expression in Circulating iNKT lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FcRn Expression in circulating monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FcgammaRII Expression in Circulating iNKT lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FcgammaRII Expression in circulating monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FcgammaRIII Expression in Circulating iNKT lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: changes in dopaminergic genes expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from Baseline in Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resolution of symptoms from initial Rome IV diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parental concern
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Day of life reaching full feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dominant hand grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Non-Dominant hand grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dominant hand pinch strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Non-Dominant hand pinch strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fatty acid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient satisfaction with post-operative pain control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Wrist actigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the appearance of facial acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in the appearance of post-acne pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Executive Function and Occupational Routines Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Short Child Occupational Profile
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quantity of day 3rd and day 5th embryos and MII oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Visual Functional Quality of life (VFQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Target lesion failure rate (TLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological volumetric measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Joint Position Sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth of cultured cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of the MPL - JAK2 pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phosphorylation of proteins in the MPL - JAK2 pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of completion of postpartum healthcare visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of RNA for early rapid diagnosis of colon cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of protein for early rapid diagnosis of colon cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean tumor-to-fibroglandular contrast ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intact parathyroid hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Successful reperfusion rate (mTICI ≥2b)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic Intracranial Hemorrhage (sICH) within 24 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Bifidobacterium spp in stool samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety with State-Trait Anxiety Inventory questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression with Beck's Depression Inventory questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post surgery hospital Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Barthel index of ADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual assessment of skin colour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Instrumental assessment of skin colour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean change of intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in chest x-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients requiring hospital attendance
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change from baseline in CAT total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feasibility of conducting LDCT screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Technical success of ERCP procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: World Health Organization Quality of Life Questionnaire (WHO-QOL-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Enrollment of probands and at-risk relatives
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response rate to baseline and follow-up surveys
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients not requiring prophylactic platelet transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients not requiring rescue therapy due to bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: DISABKIDS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Overt Tapping Accuracy at 1Hz Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Overt Tapping Accuracy at 4Hz Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in At-home Overt Tapping Accuracy at 1Hz Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in At-home Overt Tapping Accuracy at 4Hz Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of carotid web
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Suicidal ideation severity change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychological inflexibility of suicidal ideation change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Suicidal behaviors change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of enlarged clinically palpable groin nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Childhood Depression Rating Scale-Revised (CDRS-R) Remission Rates
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gut flora composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saliva flora composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Serum C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time of device positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who achieved transfusion independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number and proportion of subjects who maintained βA-T87Q-globin(HbAT87Q) at ≥2.0 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of subjects whose RBC transfusion requirement was reduced
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of couples who agree to enroll in the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of couples who complete all treatment sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average number of START Together sessions attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Burke-Fahn-Marsden dystonia rating scale-motor score (BFMDRS-M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiographic differences of HBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Echocardiographic differences of HBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dental Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Topical corticosteroid consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: The patient's global condition
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Length of ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Width of ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes